GTN: Treatment by Risk, Resistant Disease & Future Pregnancy

After molar evacuation, the FIGO diagnostic pattern includes hCG plateauing across four measurements over at least three weeks, rising across three weekly measurements over at least two weeks, or histologically diagnosed choriocarcinoma. These are clinical criteria, not instructions to wait when bleeding or other serious symptoms occur.

A persistent low positive result needs confirmation. A new pregnancy, assay interference and pituitary hCG are among the alternatives. A reference laboratory may compare serum and urine results or use another assay. GTN can often be diagnosed without a new biopsy, but suspected PSTT/ETT requires tissue assessment planned by specialists.

FIGO stage describes spread: I is confined to the uterus; II extends to other genital structures; III involves the lungs; IV involves other distant sites. The prognostic score also uses pregnancy history, interval, pretreatment hCG, tumor burden, metastatic sites and previous chemotherapy.

For invasive mole and gestational choriocarcinoma, scores 0–6 generally indicate low risk and 7 or more high risk; stage IV is high risk regardless of score. PSTT/ETT should not be assigned treatment from this scoring rule. Imaging and the current hCG result should be reviewed before treatment rather than relying on an old score.

Methotrexate with folinic acid or dactinomycin are established options. The schedule, monitoring and side effects differ. Blood counts and kidney/liver function, symptoms and serial hCG help the team decide whether treatment is working safely.

A plateau or rise during treatment may prompt a change of drug or multiagent chemotherapy. Some patients with a score of 5–6 and additional adverse features need combination treatment earlier. Consolidation continues after hCG normalization to reduce relapse risk; do not stop after the first normal test.

EMA-CO is a common multiagent regimen for high-risk GTN. Very high-risk disease—particularly a score of 13 or more, extensive burden or brain/liver involvement—may need gentler induction chemotherapy before an intensive regimen, with inpatient support to limit early hemorrhage and metabolic complications.

Brain metastases require a GTN team experienced in CNS-directed treatment. Routine whole-brain radiotherapy is not automatically part of current care; chemotherapy adaptation and selected local interventions are individualized. Heavy bleeding, fainting, coughing blood, severe breathlessness, a new severe headache or seizures need urgent medical attention.

PSTT and ETT are less sensitive to standard GTN chemotherapy and may produce relatively little hCG. Expert pathology is especially important. Hysterectomy is usually central to localized disease management; advanced or adverse-risk disease may require platinum-based chemotherapy and surgery together.

Stage and the interval from the causative pregnancy are important; an interval of about four years or longer is an adverse feature. Fertility-preserving surgery is exceptional, not an equivalent routine alternative. Follow-up is longer and cannot rely on hCG alone when the original tumor secreted little hormone.

Resistance should trigger review of the hCG trend, pathology when available, sites of disease and every previous regimen. Platinum-containing salvage chemotherapy and removal of an isolated resistant focus can be considered. Specialist referral matters before repeating an ineffective regimen.

Checkpoint inhibitors have shown activity in resistant GTN and are included in specialist salvage discussions. CAP01, for example, studied camrelizumab plus apatinib in a small, single-center phase 2 population after multiple chemotherapy failures. This is not proof that immunotherapy should replace effective first-line chemotherapy, nor a universal GTN drug approval.

Peking Union Medical College Hospital · Beijing, China

Its gynecologic team has a longstanding GTN program, including resistant disease and rare trophoblastic tumor research. Review can focus on risk classification, previous chemotherapy and the role of surgery.

MD Anderson Cancer Center · Houston, United States

Includes gestational trophoblastic disease within its gynecologic oncology service. Discuss the appropriate drug-treatment team and how treatment and reproductive follow-up will be coordinated.

Memorial Sloan Kettering Cancer Center · New York, United States

Provides care for gestational trophoblastic disease. A specialist review can clarify the diagnosis, treatment history and the plan for further care and monitoring.

Gestational trophoblastic disease (GTD) arises from pregnancy-related placental tissue. It includes complete and partial hydatidiform moles and the malignant group, GTN: invasive mole, gestational choriocarcinoma, placental-site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT). These are not ordinary endometrial cancers.

GTN may follow a molar pregnancy, miscarriage, ectopic pregnancy or term birth. Give the team your full pregnancy history. Specialist pathology, sometimes with p57 staining and genetic analysis, can resolve an uncertain molar diagnosis or distinguish gestational from other tumors.

After chemotherapy, serial hCG surveillance continues for at least a year, with the exact schedule set by the treating center; some groups need longer monitoring. Post-molar surveillance without chemotherapy follows a different schedule. Discuss reliable contraception and generally avoid pregnancy for 12 months after chemotherapy, then plan with the team.

Many patients retain fertility after successful chemotherapy. Treatment intensity, age and surgery still affect individual prospects. Ask about menstrual recovery, neuropathy, fatigue and emotional support: coping with pregnancy loss and cancer at the same time can be particularly difficult.

Bring pregnancy and evacuation dates, pathology reports/slides, all hCG results with dates and laboratory names, original scans, and a dated chemotherapy history including doses, delays and side effects. A plotted hCG curve is more useful than a single latest value.

Ask: What confirms my diagnosis? Which stage and risk group apply? Is the aim cure? What change in hCG would alter treatment? How many consolidation cycles are planned, and who will coordinate surveillance and future pregnancy care?